{"classes":[{"categories":[{"measurements":[{"comment":"\\< Lower Limit of Quantification (LLOQ) of 20 mMU/mL","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"title":"Anti-HPV 6"},{"categories":[{"measurements":[{"comment":"\\< LLOQ of 16 mMU/mL","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"title":"Anti-HPV 11"},{"categories":[{"measurements":[{"comment":"\\< LLOQ of 20 mMU/mL","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"}],"units":"Participants"}],"title":"Anti-HPV 16"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.7","upperLimit":"31.1","value":"29.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"title":"Anti-HPV 18"},{"categories":[{"measurements":[{"comment":"\\< LLOQ of 10 mMU/mL","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"}],"units":"Participants"}],"title":"Anti-HPV 31"},{"categories":[{"measurements":[{"comment":"\\< LLOQ of 8 mMU/mL","groupId":"OG000","lowerLimit":"NA","upperLimit":"8.3","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"}],"units":"Participants"}],"title":"Anti-HPV 33"},{"categories":[{"measurements":[{"comment":"\\< LLOQ of 8 mMU/mL","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"193"}],"units":"Participants"}],"title":"Anti-HPV 45"},{"categories":[{"measurements":[{"comment":"\\< LLOQ of 8 mMU/mL","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"192"}],"units":"Participants"}],"title":"Anti-HPV 52"},{"categories":[{"measurements":[{"comment":"\\< LLOQ of 8 mMU/mL","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"title":"Anti-HPV 58"}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"}],"units":"Participants"}],"description":"Anti-HPV Type 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibodies are measured using a Competitive Luminex Immunoassay. Titers are reported in milli Merck units/mL (mMU/mL).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6","id":"OG000","title":"9vHPV Vaccine"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All allocated participants who were seronegative to the appropriate HPV type at Day 1, received all 3 vaccinations with the correct dose within acceptable day ranges, provided a serum sample within 21 to 49 days postdose 3, and had no protocol deviations that could interfere with the evaluation of participant's immune response to 9vHPV vaccination.","reportingStatus":"POSTED","timeFrame":"Day 1 (predose)","title":"Geometric Mean Titers of Serotype-specific Antibodies: Predose Day 1","type":"SECONDARY","unitOfMeasure":"mMU/mL"}